In brief: ResMed, Meditech, Ventracor
Friday, 04 February, 2005
ResMed (ASX:RMD) shares were up almost 5 per cent today after the company announced record revenue and income results for the quarter ended December 31. Revenue for the quarter was US$103.9 million, a 26 per cent increase over the same quarter last year. Net income for the quarter was US$17.4 million.
Bob Moses has announced that he will not seek re-election as chairman of Meditech (ASX:MTR) at the company's annual general meeting, to be held in March. Meditech intends to appoint a new director by the end of the first quarter.
Ventracor (ASX:VCR) has received permission to begin recruiting patients for the CE Mark trial of its VentrAssist heart pump in Norway through the Rikshopitalet University Hospital in Oslo, one of the largest heart transplant centres in Europe.
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
Australia's first cases of H5 avian influenza confirmed
Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
